Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone

Dedicated reimbursement codes implemented in January 2026 provide greater clarity for physicians evaluating SRT.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Achievement reflects growing adoption of non-invasive superficial radiotherapy for the treatment of non-melanoma skin cancer

New reimbursement environment supports opportunities for broader physician adoption and expanded patient access

BOCA RATON, Fla.--(BUSINESS WIRE)-- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the sale of its 1,000th superficial radiotherapy (SRT) system, representing an important achievement in the Company's commercial development.

This sale underscores Sensus' continued efforts to expand access to SRT as a non-invasive treatment option for non-melanoma skin cancer. SRT allows physicians to treat certain skin cancers without surgical excision, offering an alternative for appropriate patients who wish to avoid surgery and its potential cosmetic and recovery considerations.

“This is a proud moment for Sensus and one that reflects years of investment in our technology, our customers and our commitment to expanding treatment options for patients,” said Joseph C. Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "We've built a strong foundation of physicians who recognize the value of SRT, and we're now seeing an exciting shift in the commercial environment. With dedicated reimbursement codes in place, greater physician awareness and growing interest from a broader range of dermatology practices, we believe the opportunity to expand adoption has never been stronger.

“Our vision has always been to make SRT a widely available treatment option for patients who can benefit from a non-invasive approach. Reaching our 1,000th system sale is a significant accomplishment, but what excites me most is the opportunity ahead as we expand our customer base, increase utilization and bring this technology to more physicians and patients,” added Sardano.

The January 2026 implementation of dedicated CPT codes for SRT has provided greater reimbursement clarity for physicians and practices evaluating the technology. Sensus continues to support adoption through physician education, flexible system acquisition models and commercial initiatives designed to increase awareness of SRT among both healthcare providers and patients.

“Very much looking forward to achieving the next 1,000 units. Thank you to all those customers who continue to show faith in our technology and to the hundreds of thousands of patients who benefit from the noninvasive treatments of SRT,” concluded Sardano.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

Forward-Looking Statements

This press release includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these statements can be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” or “potential,” or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare, Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this release as a result of the following factors, among others: the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S.; the development by others of new products, treatments, or technologies that render our technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries, including ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs on equipment we export or materials we import), or other aspects of our business; the performance of the Company’s information technology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings with the Securities and Exchange Commission. To date, geopolitical uncertainties have not had any significant impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable. Any forward-looking statements that we make in this release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date this release is filed, except as may be required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261110040327/en/

Investor Relations Contact
Leigh Salvo
New Street Investor Relations
leigh@newstreetir.com

Source: Sensus Healthcare, Inc.

Key Terms

superficial radiotherapy medical

A local radiation treatment that uses low-energy X-rays to treat conditions confined to the skin surface, delivering concentrated energy only a few millimeters deep—like using a focused flashlight rather than a floodlight. Investors care because adoption, clinical guidelines, device sales, clinic capacity and insurance reimbursement for this noninvasive option directly affect revenue and growth prospects for medical-equipment makers and outpatient providers in dermatology and oncology.

non-melanoma skin cancer medical

Non-melanoma skin cancer describes common cancers that start in the outer layers of the skin—most often basal cell and squamous cell types—and are usually linked to sun exposure. They matter to investors because they create steady, large markets for diagnostics, treatments and follow-up care (like minor surgery, topical drugs and monitoring), so developments in prevention, therapies or devices can affect healthcare revenue, regulatory risk and insurer costs.

cpt codes regulatory

CPT codes are standardized five-digit codes used to describe medical procedures, tests and services for billing, insurance reimbursement and data tracking. Think of them like barcodes for healthcare services: they tell payers what was done and influence how much providers get paid. Investors watch CPT codes because changes in coding, coverage or reimbursement rates can materially affect a healthcare provider’s revenue, equipment manufacturers’ sales and overall adoption of new treatments.